TCL Archive Proposed FDA Charges For NDA Drugs, Biologics Submissions Would Total $76 Million In FY 1990 January 27, 1989
TCL Archive In Brief: Terry To Leave NCI for Job As VP Of Revlon Health Care Group; NCI Tracking Source Of Breakthroughs June 18, 1982
TCL Archive Phase III Trial Retrospective Analysis Finds Talimogene Laherparepvec Reduced Tumors March 28, 2014